Strategic Partnerships MedTrace is pursuing on-site 15O-water perfusion quantification next to PET scanners with an onsite cyclotron, presenting a clear opportunity to engage imaging centers, nuclear medicine departments, and hospitals seeking cutting-edge perfusion analytics and streamlined workflows.

Clinical Adoption Although not yet cleared for routine use, the investigational status of 15O-water in the US and state-level approvals in Europe indicate a need for early access programs, pilot studies, and defect-free validation partnerships to accelerate regulatory clearance and payer discussions.

Key Leadership Recent appointment of a Chief Medical Officer and ongoing demonstrations of evaluation software like aQuant provide a strong narrative for clinical credibility, enabling targeted outreach to cardiology and radiology departments and executives responsible for imaging value.

Capital & Growth With substantial funding history and multi-million dollar rounds, MedTrace has the financial backing to support clinical trials, software development, and market entry activities, suggesting readiness for co-development deals and strategic investors in imaging tech.

Market Position Positioning around gold-standard 15O-water perfusion offers a differentiator in diagnostic accuracy; sales efforts can focus on centers with high demand for perfusion quantification, collaborations with imaging vendors, and integration opportunities with existing PET workflows.